US009409948B2

(12) **United States Patent**
Dong

(10) **Patent No.: US 9,409,948 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **GROWTH HORMONE RELEASING PEPTIDES**

(71) Applicant: **Ipsen Pharma S.A.S.**, Boulogne Billancourt (FR)

(72) Inventor: **Zheng Xin Dong**, Holliston, MA (US)

(73) Assignee: **Ipsen Pharma S.A.S.**, Boulogne-Billancourt (FR)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/510,188**

(22) Filed: **Oct. 9, 2014**

(65) **Prior Publication Data**

US 2015/0031615 A1 Jan. 29, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/734,314, filed on Jan. 4, 2013, now Pat. No. 8,859,729, which is a continuation of application No. 12/157,224, filed on Jun. 9, 2008, now Pat. No. 8,377,865, which is a continuation of application No. 10/484,473, filed as application No. PCT/US03/24834 on Aug. 8, 2003, now Pat. No. 7,456,253.

(60) Provisional application No. 60/402,263, filed on Aug. 9, 2002.

(51) **Int. Cl.**

C07K 7/06	(2006.01)
C07K 5/02	(2006.01)
C07K 5/062	(2006.01)
C07K 5/107	(2006.01)
C07K 5/117	(2006.01)
C07K 7/02	(2006.01)
C07K 14/60	(2006.01)
A61K 38/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 7/06*** (2013.01); ***C07K 5/0205*** (2013.01); ***C07K 5/06034*** (2013.01); ***C07K 5/1016*** (2013.01); ***C07K 5/1024*** (2013.01); ***C07K 7/02*** (2013.01); ***C07K 14/60*** (2013.01); *A61K 38/00* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,798,337	A *	8/1998	Somers	C07D 209/20 514/11.2
5,804,563	A	9/1998	Still et al.	
5,932,548	A *	8/1999	Deghenghi	A61K 38/08 514/16.4
6,124,263	A *	9/2000	Muccioli	A61K 38/29 514/11.2
7,456,253	B2 *	11/2008	Dong	C07K 5/0205 530/330
7,932,231	B2 *	4/2011	Datta	C07K 14/60 424/551
8,076,281	B2 *	12/2011	Tulipano	A61K 38/25 514/1.7
8,377,865	B2 *	2/2013	Dong	C07K 5/0205 424/1.69
8,859,729	B2 *	10/2014	Dong	C07K 5/0205 530/300
8,871,706	B2 *	10/2014	Dong	A61K 38/05 514/1.1
8,981,054	B2 *	3/2015	Datta	C07K 14/60 424/551
2002/0111461	A1 *	8/2002	Somers	A61K 38/25 530/330

FOREIGN PATENT DOCUMENTS

EP	1197496	A1	4/2002
WO	95/17423	A1	6/1995
WO	96/10040	A1	4/1996
WO	96/15148	A2	5/1996
WO	97/00894	A1	1/1997
WO	00/09537	A2	2/2000
WO	00/29011	A1	5/2000
WO	2006/045314	A2	5/2006

OTHER PUBLICATIONS

Arvat et al, "Ghrelin and synthetic GH secretagogues", Best Pract. Res. Clin. Endocrinol. Metab., 2002, 16:505-17.

Chen et al., "Analogs of the orally active growth hormone secretagogue L-162,752", Bioorganic & Med. Chem. Lett., 1996, 6:2163-69.

Guan et al., "Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues," Mol. Brain. Res., 1997, 48:23-29.

(Continued)

Primary Examiner — Maury Audet

(74) *Attorney, Agent, or Firm* — Eileen J. Ennis; Janice M. Klunder

(57) **ABSTRACT**

Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs:

$$R^1\text{-}A^1\text{-}A^2\text{-}A^3\text{-}A^4\text{-}A^5\text{-}R^2 \quad \text{(I)}$$

wherein:

A^1 is Aib, Apc or Inp;

A^2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser (Bzl), or D-Trp;

A^3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser (Bzl), or D-Trp;

A^4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl);

A^5 is Apc, Dab, Dap, Lys, Orn, or deleted;

R^1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyl(C5-14)aryl, (C3-8)cycloakyl, or (C2-10)acyl; and

R^2 is OH or NH_2;

and pharmaceutical compositions and methods of use thereof.

7 Claims, No Drawings